Exotic Nootropic Peptides vs Semax and Selank: What the Evidence Actually Shows
Dihexa, Pinealon and Cerebrolysin get talked up as next-generation nootropics. A hard look at the evidence, including a major retraction, versus the better-documented research base for Semax and Selank.
TL;DR: Evidence quality, not novelty, is the thing to compare
Dihexa, Pinealon and Cerebrolysin are marketed as advanced "nootropic peptides". Their evidence bases are wildly different from each other, and mostly weaker than their reputation. Dihexa is the cautionary tale: its two foundational mechanism papers were retracted or flagged (fabricated data), it has no human trials, and it is designed to amplify HGF/c-Met, a pathway linked to cancer biology. Pinealon rests on single-research-school preclinical work with a contested mechanism and no human RCT. Cerebrolysin actually has placebo-controlled human trials, but it is a porcine-brain-derived intravenous prescription biologic, a different category entirely, not a self-administered research peptide. Semax and Selank are not "proven" either, but they are the better-documented research-peptide choice: published preclinical findings, an actual (non-randomized, non-placebo-controlled) clinical literature, established chemistry, and no retracted papers.
Every few months a new "exotic" nootropic peptide gets talked up as the next big thing. This article does the unglamorous work of comparing them on the axis that matters: how good is the evidence, really. It covers the non-stocked exotics (Dihexa, Pinealon, Cerebrolysin, and the near-unstudied Adamax) strictly as scientific comparison, and it explains why the two nootropic peptides we do stock, Semax and Selank, are the better-evidenced choice, without overclaiming for them either. Everything is written for laboratory research context only, with no dosing and no usage guidance. Conditions such as Alzheimer's disease or anxiety are named only to describe what published studies investigated.
Neuroprotective and nootropic peptides
How to Read Nootropic-Peptide Evidence
Before the compounds, a quick literacy note, because the evidence here spans four very different tiers:
- Placebo-controlled randomized trial: the strongest tier (Cerebrolysin has some).
- Non-randomized, non-placebo-controlled clinical data: real human exposure but weak design (Semax, Selank).
- Preclinical only: cell or rodent mechanism, no human data (Pinealon, and Dihexa's one surviving study).
- Retracted or misconduct-tainted: evidence that has been withdrawn from the record (Dihexa's foundational papers).
A striking finding in a mouse does not transfer to humans, and a retracted paper is not weak evidence, it is no evidence. Keep those tiers in mind for everything below.
Dihexa: The Cautionary Tale
Dihexa is an angiotensin-IV-derived analogue promoted as orally active and blood-brain-barrier-permeant, on the claim that it potentiates HGF/c-Met signalling and downstream PI3K/AKT to drive dendritic arborization and synaptogenesis. The problem is what happened to the evidence for that claim.
The foundational Dihexa papers were retracted
The foundational paper claiming Dihexa's procognitive and synaptogenic effects are mediated by HGF/c-Met activation was retracted in April 2025 for falsified and fabricated data (PMID 25187433), and a related 2012 angiotensin-IV/HGF analogue paper from the same group carries retraction and expression-of-concern flags (PMID 22129598); the lead laboratory had research-misconduct findings across multiple papers. These are cited here only to document their retracted or flagged status, not as evidence. After excluding the retracted and flagged foundational literature, essentially one independent study remains: a 2021 mouse study reporting that Dihexa restored spatial memory in an Alzheimer's-model mouse and reduced neuroinflammation via PI3K/AKT (PMID 34827486). That is a single rodent study, and Dihexa has no human trials and no published human safety profile.
There is a second, mechanistic reason for caution. Dihexa is engineered to amplify HGF/c-Met, an axis that is a well-established driver of cell proliferation, migration and tumour invasion (standard cancer biology). A compound built to push that pathway harder therefore carries a theoretical tumour-promotion concern, with zero human safety data either way. This is a mechanistic red flag, not a proven cancer risk, but it is exactly the kind of flag that belongs on the label. Dihexa is not sold here, and this section exists only to explain why.
Pinealon: Single-School Preclinical Evidence
Pinealon (the tripeptide Glu-Asp-Arg, EDR) is a "peptide bioregulator" from the Khavinson research school, proposed to enter cells and the nucleus and epigenetically modulate gene expression. The cleanest indexed preclinical result is a 2021 mouse study in which the EDR and KED tripeptides prevented hippocampal dendritic-spine loss and trended toward restoring long-term potentiation in a 5xFAD Alzheimer's-model mouse (PMID 34071923).
The honest caveat: Pinealon's evidence is thin, largely Russian-language, and concentrated in a single research school, and its signature nuclear/epigenetic mechanism is asserted by that group rather than independently established. There are no human RCTs. It is not stocked and is discussed here for comparison only.
Cerebrolysin: Real Trials, But a Different Category
Cerebrolysin is the outlier, because it genuinely has placebo-controlled human data. In a 28-week double-blind RCT of 149 patients with mild-to-moderate Alzheimer's disease, Cerebrolysin improved cognition (an ADAS-cog advantage of about 3.2 points, p less than 0.0001) and global impression versus placebo (PMID 11552768), and a placebo-controlled pilot in 41 vascular-dementia patients found ADAS-cog improvement and reduced qEEG slowing (PMID 18048059). Pharmacologically it is characterized as a peptide preparation that mimics endogenous neurotrophic factors (PMID 22514792).
Cerebrolysin is not a self-administered peptide
Cerebrolysin is a porcine-brain-derived, low-molecular peptide and amino-acid preparation administered as a parenteral prescription preparation. It is a regulated prescription biologic in several jurisdictions, several of its trials are manufacturer-linked, and its meta-analytic effects are modest and heterogeneous. It is a different category from a small synthetic research peptide, it is presented here purely as clinical context, and it is not something a reader can or should self-administer. It is not sold here.
A brief word on Adamax and similar ultra-obscure Semax-like analogues: essentially no indexed human or robust preclinical evidence was found. They are unstudied, not characterized nootropics, and buyer-beware is the only honest framing.
Semax: Reproducible Preclinical Mechanism Plus Real (If Limited) Human Data
Semax is a synthetic heptapeptide analogue of the ACTH(4-10) fragment (Met-Glu-His-Phe-Pro-Gly-Pro). Its preclinical mechanism is reproducible: a dose stimulated BDNF expression across multiple rat brain regions in vivo (PMID 14556513), and in rats a dose produced a roughly 1.4-fold rise in hippocampal BDNF protein, a roughly 1.6-fold rise in trkB phosphorylation and higher BDNF and trkB mRNA, alongside improved passive-avoidance learning (PMID 16996037). In about 110 post-ischemic-stroke patients, Semax was associated with raised plasma BDNF and faster functional recovery, though that study was non-randomized and not placebo-controlled (PMID 29798983).
Note the honesty here: the rodent BDNF effect is modest (about 1.4-fold), and the human data is non-blinded. "Raises BDNF in a rat" is a mechanistic signal, not a demonstrated cognitive benefit in people.
Brain-boosting nootropic peptide derived from ACTH. Increases BDNF (brain-derived neurotrophic factor), enhances focus, memory, and mental clarity. Widely used in Russian clinical practice for cognitive enhancement.
Selank: Tuftsin Analogue With an Anxiolytic Research Profile
Selank is a synthetic analogue of the endogenous immunomodulatory tetrapeptide tuftsin. The verified rodent finding is increased hippocampal BDNF. In a Russian clinical trial of 62 patients with generalised anxiety disorder and neurasthenia, Selank produced anxiolytic effects broadly similar to the benzodiazepine medazepam, with additional antiasthenic effects, but there was no placebo arm (PMID 18454096). In rats, Selank increased hippocampal Bdnf mRNA at 3 hours and BDNF protein at 24 hours (PMID 18841804).
Synthetic tuftsin analog with anxiolytic, nootropic, and immunomodulatory properties. Developed at the Russian Academy of Sciences.
The Semax and Selank Mix
Semax and Selank have been studied separately, and the two are offered as a combined laboratory-research blend. The honest note: no dedicated study has established any cognitive, affective or other effect of the mixture; findings from the separate single-compound studies cannot be attributed to the blend.
Pre-mixed combination of the two leading nootropic peptides in one vial. Semax boosts focus and BDNF, Selank reduces anxiety and enhances calm. Together they provide balanced cognitive enhancement for research.
Side by Side
- Human data
- None
- Mechanism integrity
- One paper retracted, related paper flagged; 1 independent mouse study
- Category
- Synthetic peptide
- Stocked
- No (comparison only)
- Human data
- None
- Mechanism integrity
- Single-school preclinical, contested mechanism
- Category
- Synthetic tripeptide
- Stocked
- No (comparison only)
- Human data
- Placebo-controlled RCTs
- Mechanism integrity
- Reviewed, non-retracted
- Category
- IV prescription biologic
- Stocked
- No (comparison only)
- Human data
- Non-randomized clinical
- Mechanism integrity
- Two cited rat studies (modest)
- Category
- Synthetic peptide
- Stocked
- Yes
- Human data
- Active-comparator trial, no placebo
- Mechanism integrity
- One cited rat BDNF study
- Category
- Synthetic peptide
- Stocked
- Yes
Why Semax and Selank are the better-evidenced research choice
Not because they are proven (they are not: their human data is non-randomized and mostly non-placebo-controlled, and their rodent effects are modest, with two cited rat studies for Semax and one for Selank). Compared specifically with Dihexa, Pinealon and Adamax, they rest on published rodent findings, an actual human clinical literature and established chemistry, and they do not carry the retracted-foundation problem or Dihexa's specific proposed HGF/c-Met concern. Dihexa rests on retracted or misconduct-tainted data, Pinealon on single-school unreplicated claims, and Cerebrolysin belongs to a different pharmaceutical category. None of these compounds is an EU-approved medicine; Semax and Selank hold approvals only in Russia and Ukraine.
Selank laboratory research
Research Context and Handling
Semax, Selank and the Semax/Selank blend are supplied strictly for laboratory research and are not intended for human consumption. Dihexa, Pinealon, Cerebrolysin and Adamax are discussed for scientific comparison only and are not offered for sale. This article gives no dosing, administration routes or protocols for any compound. Verify identity and purity of the stocked peptides against a batch-specific third-party Certificate of Analysis, and see the Semax and Selank nootropic overview and the BDNF research explainer for more.
Frequently Asked Questions
This article is for research and educational purposes only. Non-stocked compounds are discussed strictly for scientific comparison, and retracted publications are cited only to document their retraction. Conditions are named only to describe what published research investigated. Nothing here is medical advice, a health claim, dosing guidance or a recommendation for use. Stocked compounds are sold exclusively for laboratory research.
Research context for English-speaking buyers
Most of our English-speaking customers ship to the UK, Ireland, Malta or other English-as-second-language EU territories. The regulatory picture differs per country.
- Relevant authorities
- MHRA (UK, post-Brexit), HPRA (Ireland, EU-aligned), FDA Section 503A bulks list (US, restricted Cat 2 status of several peptides as of 2026)
- Customs and VAT
- EU shipments include 19% VAT; UK shipments after Brexit are now extra-EU and may attract UK VAT plus a handling fee at import
- Typical shipping window
- EU 2-4 working days, UK 4-7 working days, other international 7-14 working days, depending on customs
Research-grade peptides shipped from our EU warehouse are sold for laboratory use only and are not authorised for human or veterinary therapeutic application in any of the destination jurisdictions. US customers should be aware that the FDA Section 503A bulks list classification (and the April 2026 reclassification of twelve compounds) only governs compounding pharmacies, not direct-to-researcher imports for non-clinical work. UK buyers should declare the consignment on import and may be asked for a research justification by HMRC. We provide a CoA per batch identified by colour code rather than serial number; customs sometimes asks for this document when clearing the parcel.